Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):ONLS
Pharmacodynamics:The aminocaproic acid derivative, not suppressing fibrinolysis. Has anti-edematous effect, stimulates regeneration, growth of granulations, formation of bone callus.
Clears the wound surfaces from necrotic masses, ensures the engraftment of grafts.
Pharmacokinetics:Not studied.
Indications:It is used for wound healing, for the formation of postoperative cosmetic sutures, in order to accelerate bone fusion during fractures and for engrafting of auto- and homotransplants.
XIII.M80-M85.M84.2 Slow fracture fusion
XIX.T20-T32.T30.0 Thermal burn, unspecified degree of unspecified site
Contraindications:Wound infection, purulent inflammation.
Individual intolerance.
Carefully:Increased individual sensitivity to the drug.
Pregnancy and lactation:Pregnancy and lactation: recommendations for Food and Drug Administration (US Food and Drug Administration) - not determined. Application for pregnant and lactating women is contraindicated.
Dosing and Administration:Outer: 5% ointment is applied to the disinfected wound surface daily. The course of treatment is from 10 to 30 days.
Inside: 20 ml of 25% solution 3 times a day. For fractures of bones - 20 ml 2 times a day for 10 days. After X-ray control, if necessary, the course of treatment begins anew and continues until the bone becomes fully fused.
The highest daily dose: 500 mg.
The highest single dose: 1.5 g.
Side effects:Allergic reactions.
Interaction:Clinically significant interactions are not described.
Special instructions:In the treatment of wound surfaces, a combined use of the drug - inside and locally.